Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers

Anesthesiology

Volumn 92, Issue 4, 2000, Pages 993-1001

  Ericsson, Hans ^a   Bredberg, Ulf ^b   Eriksson, Ulf ^b   Jolin Mellgård, Åse ^b   Nordlander, Margareta ^b   Regårdh, Carl G ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b NONE

Author keywords

Arteriovenons; Context sensitive times; Decrement times

Indexed keywords

CLEVIDIPINE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; INFUSION; MALE; MEAN ARTERIAL PRESSURE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034079587     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200004000-00016     Document Type: Article

References (34)

1. van Zwieten PA, van Wezel HB: Antihypertensive drug treatment in the perioperative period. J Cardiothorac Vasc Anesth 1993; 7:213-26
2. Levy JH: The ideal agent for perioperative hypertension and potential cytoprotective effects. Acta Anaesthesiol Scand Suppl 1993; 37:20-5
3. Lawrence CJ, Lestrade A, De Lange S: Comperative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery. Acta Anaestesiol Scand Suppl 1993; 37:48-52
4. Cook E, Clifton GG, Vargas R, Bienvenu G, Williams R, Sambol N, MacMahon G, Grandy S, Lai CM, Quon C, Anderson CR, Turlapaty P, Wallin JD: Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine. Clin Pharmacol Ther 1990; 47:706-18
5. Levy JH, Huraux C, Nordlander M: Treatment of perioperative hypertension, Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia, Hanely and Belfus, 1997, pp 345-58
6. Ericsson H, Tholander B, Regårdh CG: In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci 1999; 8:29-37
7. Ericsson H, Fakt C, Höglund L, Jolin-Mellgård Å, Nordlander M, Sunzel M, Regårdh CG: Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol 1999; 55:61-7
8. Jacobs JR, Croughwell ND, Goodman DK, White WD, Reves JG: Effect of hypothermia and sampling site on blood esmolol concentrations. J Clin Pharmacol 1993; 33:360-5
9. Donati F, Varin F, Ducharme J, Gill SS, Theoret Y, Bevan DR: Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. Clin Pharmacol Ther 1991; 49: 515-22
10. Hermann DJ, Egan TD, Muir KT: Influence of arteriovenous sampling on remifentanil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1999; 65:511-8
11. Vuylsteke A, Milner QJ, Ericsson H, Mur D, Dunning J, Latimer RD: Therapeutic dose rates and pharmacokinetics of clevidipine in patients undergoing coronary artery bypass surgery (abstract). Br J Anaesth 1998; 80:A11
12. Holm G, Hanssen K, Svensson L: Use of dodecyl sulfate as an esterase inhibitor before gas-chromatographic determination of labile β-adrenoceptor blocking drugs. Clin Chem 1985; 31:868-70
13. Fakt C, Stenhoff H: Determination of an ultrashort-acting antihypertensive dihydropyridine, clevidipine, in blood using capillary gas chromatography mass spectrometry and of the primary metabolite using liquid chromatography and fluorescence detection. J Chromatogr B Biomed Appl 1999; 723:211-9
14. Yamaoka K, Nakagawa T, Uno T: Application of Akaiki's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1976; 6:165-75
15. Gibaldi M, Perrier D: Pharmacokinetics, 2nd edition. New York, Decker, 1982
16. Hughes M, Glass P, Jacobs J: Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. ANESTHESIOLOGY 1992; 76:334-41
17. Shafer SL, Varvel JR: Pharmacokinetics, pharmacodynamics, and rational opioid selection. ANESTHESIOLOGY 1991; 74:53-63
18. Kieler-Jensen N, Jolin-Mellgård Å, Nordlander M, Ricksten SE: Myocardial circulatory and metabolic effects of clevidipine after coronary artery bypass grafting (CABG). Br J Anaesth 1997; 78:A12
19. Ericsson H: The pharmacokinetics and pharmacodynamics of clevidipine, a new ultrashort-acting calcium antagonist, in different animal species and man [doctoral thesis]. Uppsala, Sweden: Uppsala University; 1999
20. Armstrong PW, Moffat JA, Marks GS: Arterial-venous nitroglycerin gradient during intravenous infusion in man. Circulation 1982; 666:1273-6
21. Kreye VA, Reske SN: Possible site of the in vivo disposition of sodium nitroprusside in the rat. Naunyn-Schmiedebergs Arch Pharmacol 1982; 320:260-5
22. Chiou WL: The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: I. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics Clin Pharmacokinet 1989; 17:175-99
23. Chiou WL: The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: II. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics. Clin Pharmacokinet 1989; 17:275-90
24. Egan TD, Lemmens HJ, Fiset P, Hermann DJ, Muir KT, Stanski DR, Shafer SL: The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ANESTHESIOLOGY 1993; 79:881-92
25. Gourley SG, Benowitz NL: Arteriovenous differences in plasma concentration of nicotine and cathecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997; 62:453-63
26. Opie LH: Fundamental properties: Mechanisms, classification, sites of action, Clinical Use of Calcium Channel Antagonist Drugs. Norwell, MA: Kluwer Academic Publisher, 1990, pp 28-70
27. Folkow B, Neil E: Circulation. New York, Oxford University Press, 1971
28. Kleinbloesem CH, Van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD: Rate of increase in plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans. Clin Pharmacol Ther 1987; 41:26-40
29. Cohen AF, van Hall MA, van Harten J, Schoemaker RC, Johansson P, Breimer DD, Visser R, Edgar B: The influence of infusion rate on the hemodynamic effects of felodipine. Clin Pharmacol Ther 1990; 48:309-17
30. Francheteau P, Steimer J, Merdjan H, Guerret M, Dubray C: A mathematical model for dynamics of cardiovascular drug action: Application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharm 1993; 21:489-514
31. Jacobs JR, Nath PA: Compartment model to describe peripheral arterial-venous drug concentration gradients with drug elimination from the venous sampling compartment. J Pharm Sci 1995; 84:370-5
32. Sheiner LB: Clinical pharmacology and the choice between theory and empiricism. Clin Pharmacol Ther 1989; 46:605-15
33. Gumbleton M, Oie S, Verotta D: Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arteriovenous drug concentration differences. Br J Clin Pharmacol 1994; 38:389-400
34. Tuk B, Danhof M, Mandema JW: The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J Pharmacokin Biopharm 1997; 25:39-62